A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma

Alan Chan, Carolyn Dang, Jessica Wisniewski, Xiuhua Weng, Edward Hynson, Lixian Zhong, Leslie Wilson

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences